GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes

$443,381
A. McGarry Houghton · Fred Hutchinson Cancer Research Center · R01 · FY2019 · CA

Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer

$443,233
Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2023 · CA

Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy efficacy in pancreatic cancer

$443,233
Meredith A Morgan · University Of Michigan At Ann Arbor · R01 · FY2022 · CA

The Role of Schwann Cells in the Progression of Melanoma

$443,178
Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA

Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer

$442,930
Andrew J Armstrong · Duke University · R01 · FY2023 · CA

Novel IL-12 Gene Delivery Vehicles for Transformation of Solid Tumors

$442,717
Seth M Pollack · Northwestern University At Chicago · R01 · FY2021 · CA

Bone marrow-derived myeloid cell dysregulation in malignant progression of glioma

$442,594
Prajwal Rajappa · Research Inst Nationwide Children'S Hosp · R01 · FY2024 · NS

Regulation of the Mitotic Checkpoint by Gsk3

$442,500
William R Taylor · University Of Toledo · R15 · FY2017 · GM

Targeting melanoma promoting RNA modification pathway for melanoma therapy.

$442,236
Narendra Wajapeyee · University Of Alabama At Birmingham · R01 · FY2025 · CA

Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancer

$442,214
Donald W. Kufe · Dana-Farber Cancer Inst · R21 · FY2022 · CA

Novel mechanisms regulating PD-1 signaling and function

$442,212
Adam Mor · Columbia University Health Sciences · R01 · FY2022 · AI

From the Past to the Future: Chimeric Antigen Receptor T cells for Lymphoid Malignancies

$442,180
Joseph Anthony Fraietta · University Of Pennsylvania · P01 · FY2023 · CA

The replication checkpoint and genomic fidelity in skin

$442,018
Paul Nghiem · University Of Washington · R01 · FY2010 · AR

Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy

$441,967
Stephen Matthew Hatfield · Northeastern University · R01 · FY2024 · EB

Role of Macrophage in Osteoimmunology with Aging

$441,855
Zhenqiang Yao · University Of Rochester · R01 · FY2023 · AG

Role of Macrophage in Osteoimmunology with Aging

$441,855
Zhenqiang Yao · University Of Rochester · R01 · FY2022 · AG

Project 3: Chemokine modulation in TME for enhanced TLS formation and cross-priming/ recruitment of therapeutic CD8+ TILs

$441,751
Walter J Storkus · Roswell Park Cancer Institute Corp · P01 · FY2021 · CA

Overcoming primary and secondary resistance in wild-type BRAF melanoma

$441,736
Andrew E Aplin · Wistar Institute · P01 · FY2023 · CA

Targeting ER+ Breast Cancer Through Induced Viral Mimicry

$441,716
Charles H Spruck · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2022 · CA

Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma

$441,695
Markus Schober · New York University School Of Medicine · R01 · FY2022 · CA

Checkpoints of TNF Gene Regulation

$441,667
Anne Goldfeld · Boston Children'S Hospital · R01 · FY2015 · GM

Regulation of Tumor Immunogenicity in Glioblastoma

$441,658
Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2024 · NS

Targeting NQO1+ tumor to trigger innate and adaptive immunity

$441,498
Xiumei Huang · Indiana University Indianapolis · R01 · FY2023 · CA

Targeting Epigenomic Regulators at the Replication Fork in PDAC

$441,252
Gwen Lomberk · Medical College Of Wisconsin · R01 · FY2022 · CA

Studies of DNA damage checkpoints

$441,095
Scripps Research Institute · R01 · FY2003 · CA